• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Drugs in Development

To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. 

For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.

Clinical Trial Information

Here are links to databases of known clinical trials for ALS/MND.

  • ALS/MND Clinical Trial Navigator: The ALS Therapy Development Institute created the ALS Trial Navigator is a comprehensive resource for making informed decisions about participating in ALS/MND clinical trials. Use this innovative tool learn about clinical trials and get a personalized list of ALS/MND trials based on your eligibility and preferences. (Language: English)
  • ALS International Clinical Trial Database: The Associazione conSLAncio Onlus created the ALS/MND International Clinical Trial Database. Built on a multi-lingual website, this features users to view the current status of clinical trials taking place at sites in, or close to, Italy. Each trial is linked to the official trial registry where users can directly access study objectives, eligibility criteria and study contacts. (Language: Italian)
  • HEALEY ALS Platform Trial: The HEALEY ALS Platform Trial aims to accelerate the process of drug development and the path for effective treatment for ALS/MND by testing multiple drugs simultaneously and adaptively. This design has been seen to be successful in cancer trials. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to receive either the study drug or placebo. New regimens will be continuously added as new investigational products become available. The trial is recruiting in the United States only and will enroll additional participants as each new regimen is available. (Language: English)

Information on Drugs in Clinical Trial

Here are briefing notes from the International Alliance’s Scientific Advisory Council on drugs and therapies currently being researched.

SPG302

Masitinib

Pridopidine

NP001

Neuronata-R / Lenzumestrocel

Ulefnersen

NurOwn

CNM-Au8

AstroRx

ILB

PrimeC

SOD1-Targeted Therapies & Trials

Regulatory T Cell Enhancing Therapies

C9orf72 Therapies and Trials

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Jon Newsome, USA

    Jon Newsome, USA

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Rosie Riley, USA

    Rosie Riley, USA

  • Dr. Janmejay Pradhan, India

    Dr. Janmejay Pradhan, India

  • Timmy, Belgium

    Timmy, Belgium

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Amparo Muriel Engativa, Colombia

    Amparo Muriel Engativa, Colombia

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Susan Keldani, USA

    Susan Keldani, USA

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Phil Rossall, UK

    Phil Rossall, UK

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Olga, Argentina

    Olga, Argentina

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Hans Dieter Olszewski, Germany

    Hans Dieter Olszewski, Germany

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Wendy Hendrickson, USA

    Wendy Hendrickson, USA

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Michael Lee, Australia

    Michael Lee, Australia

  • Willi Klein, UK

    Willi Klein, UK

  • Anderson Custodio Pinto, Brazil

    Anderson Custodio Pinto, Brazil

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Sally Pauls, USA

    Sally Pauls, USA

  • Mike Small, UK

    Mike Small, UK

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login